This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


EPIRUS Biopharmaceuticals, Inc.

Drug Names(s): low dose budesonide/nortriptyline

Description: CRx-170 is a combination product consisting of low doses of budesonide (a steroid) and nortriptyline. Nortriptyline is thought to complement budesonide’s reduction of inflammatory cytokine activity. The goal of the combination treatment is to lower the dose of the steroid needed for an anti-inflammatory effect, thereby reducing side effects.

Deal Structure: Epirus and Zalicus
In April 2014, Epirus and Zalicus announced that they have entered into a definitive agreement under which Epirus will merge with Zalicus in an all-stock transaction. Following closing, Zalicus will be re-named Epirus Biopharmaceuticals.

In July 2014, EPIRUS Biopharmaceuticals announced the completion of a merger with Zalicus. The combined company, which has been renamed EPIRUS Biopharmaceuticals, will focus on the business of EPIRUS and operate under the leadership of the EPIRUS management team.

CRx-170 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug